ATE187889T1 - Vorbeugung und behandlung der peripheren neuropathie - Google Patents

Vorbeugung und behandlung der peripheren neuropathie

Info

Publication number
ATE187889T1
ATE187889T1 AT93915178T AT93915178T ATE187889T1 AT E187889 T1 ATE187889 T1 AT E187889T1 AT 93915178 T AT93915178 T AT 93915178T AT 93915178 T AT93915178 T AT 93915178T AT E187889 T1 ATE187889 T1 AT E187889T1
Authority
AT
Austria
Prior art keywords
peripheral neuropathy
prevention
treatment
igf
insulin
Prior art date
Application number
AT93915178T
Other languages
English (en)
Inventor
Michael E Lewis
Stuart C Apfel
John A Kessler
Original Assignee
Cephalon Inc
Einstein Coll Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/051,191 external-priority patent/US5420112A/en
Application filed by Cephalon Inc, Einstein Coll Med filed Critical Cephalon Inc
Application granted granted Critical
Publication of ATE187889T1 publication Critical patent/ATE187889T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Surgical Instruments (AREA)
  • External Artificial Organs (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
AT93915178T 1992-06-12 1993-06-01 Vorbeugung und behandlung der peripheren neuropathie ATE187889T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89907092A 1992-06-12 1992-06-12
US08/051,191 US5420112A (en) 1992-06-12 1993-04-16 Prevention and treatment of peripheral neuropathy
PCT/US1993/005203 WO1993025219A1 (en) 1992-06-12 1993-06-01 Prevention and treatment of peripheral neuropathy

Publications (1)

Publication Number Publication Date
ATE187889T1 true ATE187889T1 (de) 2000-01-15

Family

ID=26729153

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93915178T ATE187889T1 (de) 1992-06-12 1993-06-01 Vorbeugung und behandlung der peripheren neuropathie

Country Status (16)

Country Link
US (3) US5633228A (de)
EP (1) EP0659083B1 (de)
JP (1) JP3623502B2 (de)
AT (1) ATE187889T1 (de)
AU (1) AU683215B2 (de)
CA (1) CA2136969C (de)
DE (1) DE69327402T2 (de)
DK (1) DK0659083T3 (de)
ES (1) ES2140463T3 (de)
FI (1) FI945840A0 (de)
GR (1) GR3032844T3 (de)
HU (1) HU217543B (de)
NO (1) NO309705B1 (de)
NZ (2) NZ253867A (de)
PT (1) PT659083E (de)
WO (1) WO1993025219A1 (de)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09509140A (ja) * 1993-11-15 1997-09-16 セルトリックス ファーマシューティカルズ，インコーポレイテッド 神経学的障害の治療方法
US5728676A (en) * 1994-09-08 1998-03-17 Ciba-Geigy Corporation Use of insulin-like growth factors I and II for inhibition of inflammatory response
US5741776A (en) * 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
US20030069177A1 (en) 2000-05-16 2003-04-10 Genentech, Inc. Method for treating cartilage disorders
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
EP0981545B1 (de) * 1997-05-05 2006-09-13 Mayo Foundation For Medical Education And Research IGFIIE/ IGFBP2 Komplex
US6916790B2 (en) 1997-05-05 2005-07-12 Mayo Foundation For Medical Education And Research Treatment of osteoporosis
US6548482B1 (en) 1997-05-05 2003-04-15 Mayo Foundation For Medical Education And Research Treatment of osteoporosis
AU1080899A (en) 1997-10-14 1999-05-03 Nadine A. Tatton Methods for increasing schwann cell survival
DK1047449T3 (da) * 1997-10-28 2004-01-26 Univ British Columbia Immunologiske præparater og anvendelse deraf til forbigående ændring af myelin i centralnervesystemet hos pattedyr for at fremme neuronal regenerering
ES2146530B1 (es) * 1997-12-26 2001-04-16 Consejo Superior Investigacion Utilizacion del factor de crecimiento igf-i en la fabricacion de composiciones utiles en el tratamiento de la ataxia cerebelar.
US6043259A (en) * 1998-07-09 2000-03-28 Medicure Inc. Treatment of cardiovascular and related pathologies
CA2356109C (en) 1999-01-06 2008-04-22 Genentech, Inc. Insulin-like growth factor (igf) i mutant variants
EP1169322B8 (de) 1999-03-08 2006-09-13 Medicure Inc. Pyridoxal-analoge zur behandlung von störungen ausgelöst durch einen vitamin b6 mangel
US20050008641A1 (en) * 1999-04-28 2005-01-13 University Of British Columbia Composition for neuronal regeneration comprising myelin-specific antibodies and complement proteins
AU5840200A (en) * 1999-07-13 2001-01-30 Medicure Inc. Treatment of diabetes and related pathologies
EP1872797A3 (de) 1999-08-24 2008-04-02 Medicure International Inc. Behandlung kardiovaskulärer und verwandter Leiden
US6642038B1 (en) 1999-09-14 2003-11-04 Genzyme Glycobiology Research Institute, Inc. GlcNAc phosphotransferase of the lysosomal targeting pathway
US6770468B1 (en) 1999-09-14 2004-08-03 Genzyme Glycobiology Research Institute, Inc. Phosphodiester-α-GlcNAcase of the lysosomal targeting pathway
US6632429B1 (en) 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US7442689B2 (en) * 2000-02-29 2008-10-28 Medicure International Inc. Cardioprotective phosphonates and malonates
EP1268498B1 (de) 2000-02-29 2005-04-13 Medicure International Inc. Cardioprotektive phosphonate
US6586414B2 (en) 2000-03-28 2003-07-01 Medicure International Inc. Treatment of cerebrovascular disease
US6897228B2 (en) * 2000-07-07 2005-05-24 Medicure International Inc. Pyridoxine and pyridoxal analogues: new uses
DE60128912T9 (de) 2000-07-07 2008-06-26 Medicure International Inc. Pyridoxin- und pyridoxalanaloga als cardiovasculäre therapeutika
US6548519B1 (en) 2001-07-06 2003-04-15 Medicure International Inc. Pyridoxine and pyridoxal analogues: novel uses
WO2002014537A2 (en) * 2000-08-14 2002-02-21 Fallon Joan M Methods for diagnosing and treating dysautonomia and other dysautonomic conditions
US20070053895A1 (en) 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
CA2847458C (en) 2000-12-13 2019-11-12 Baylor College Of Medicine Defects in periaxin associated with myelinopathies
CN100439397C (zh) * 2001-02-09 2008-12-03 基因技术股份有限公司 Igf-1的结晶
US20040121988A1 (en) * 2001-03-28 2004-06-24 Medicure International Inc. Treatment of cerebrovascular disease
ATE435852T1 (de) 2001-05-24 2009-07-15 Neuren Pharmaceuticals Ltd Gpe-analoga und peptidomimetika
US20070004641A1 (en) * 2001-05-24 2007-01-04 Neuren Pharmaceuticals Limited Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamate
US7605177B2 (en) * 2001-05-24 2009-10-20 Neuren Pharmaceuticals Limited Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration
US7714020B2 (en) * 2001-05-24 2010-05-11 Neuren Pharmaceuticals Limited Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
US20030124652A1 (en) * 2001-12-21 2003-07-03 Novazyme Pharmaceuticals, Inc. Methods of producing high mannose glycoproteins in complex carbohydrate deficient cells
US6800472B2 (en) * 2001-12-21 2004-10-05 Genzyme Glycobiology Research Institute, Inc. Expression of lysosomal hydrolase in cells expressing pro-N-acetylglucosamine-1-phosphodiester α-N-acetyl glucosimanidase
US6905856B2 (en) * 2001-12-21 2005-06-14 Genzyme Glycobiology Research Institute, Inc. Soluble GlcNAc phosphotransferase
ES2207387B1 (es) * 2002-02-28 2005-07-16 Consejo Sup. Investig. Cientificas Composicion quimica de igf-i para el tratamiento y prevencion de enfermedades neurodegenerativas.
US20040186077A1 (en) * 2003-03-17 2004-09-23 Medicure International Inc. Novel heteroaryl phosphonates as cardioprotective agents
EP1773370A1 (de) * 2004-07-07 2007-04-18 Medicure International Inc. Kombinationstherapien mit thrombozytenaggregations-arzneimitteln
US20070060549A1 (en) * 2004-08-10 2007-03-15 Friesen Albert D Combination therapies employing ace inhibitors and uses thereof for the treatment of diabetic disorders
EP1791551B1 (de) * 2004-08-30 2020-02-26 Ipsen Biopharmaceuticals, Inc. Verfahren und vorrichtung zur diagnose und behandlung von mangelstörung an insulinähnlichem wachstumsfaktor
US20060198838A1 (en) * 2004-09-28 2006-09-07 Fallon Joan M Combination enzyme for cystic fibrosis
US7459468B2 (en) * 2004-10-28 2008-12-02 Medicure International, Inc. Aryl sulfonic pyridoxines as antiplatelet agents
WO2006050598A1 (en) * 2004-10-28 2006-05-18 Medicure International Inc. Dual antiplatelet/anticoagulant pyridoxine analogs
US20060094749A1 (en) * 2004-10-28 2006-05-04 Medicure International Inc. Substituted pyridoxines as anti-platelet agents
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US20070116695A1 (en) * 2005-09-21 2007-05-24 Fallon Joan M Pharmaceutical preparations for attention deficit disorder, attention deficit hyperactivity disorder and other associated disorders
JP2009517411A (ja) * 2005-11-28 2009-04-30 メディキュア インターナショナル インコーポレーテッド 心血管及び関連病状の処置のための調剤
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US9320780B2 (en) * 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
ES2732453T3 (es) * 2008-07-01 2019-11-22 Curemark Llc Métodos y composiciones para el tratamiento de síntomas de trastornos neurológicos y de salud mental
US10776453B2 (en) * 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
CA3050530A1 (en) 2009-01-06 2010-07-15 Galenagen, Llc Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus on surfaces
JP2012514604A (ja) 2009-01-06 2012-06-28 キュレロン リミテッド ライアビリティ カンパニー 大腸菌（Ｅ．ｃｏｌｉ）による経口感染の治療または予防のための組成物および方法
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
AU2011223706A1 (en) * 2010-03-05 2012-09-20 Baylor Research Institute Involvement of androgen/androgen receptor pathway in Fabry disease
CA2823505A1 (en) * 2011-01-26 2012-08-02 Megmilk Snow Brand Co., Ltd. Agent for improving peripheral sensitivity of skin
MX362974B (es) 2011-04-21 2019-02-28 Curemark Llc Compuestos para el tratamiento de alteraciones neuropsiquiatricas.
US9221890B2 (en) 2011-10-25 2015-12-29 Indiana University Research And Technology Corporation Gigaxonin fusion protein and methods for treating giant axonal neuropathy
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
AU2018250823A1 (en) 2017-04-10 2019-10-17 Curemark, Llc Compositions for treating addiction
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1275922C (en) * 1985-11-28 1990-11-06 Harunobu Amagase Treatment of cancer
SE8703625D0 (sv) * 1987-09-18 1987-09-18 Kabivitrum Ab New medical use
JP2507106B2 (ja) * 1987-12-24 1996-06-12 グロペップ プロプライエタリー リミテッド インスリン様成長因子１（ｉｇｆ―１）または因子２（ｉｇｆ―２）の類縁ペプチド
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
DE69218948T2 (de) * 1991-08-01 1997-07-31 Auckland Uniservices Ltd IGF-I zur Verbesserung der neuronale Lage
US5420112A (en) * 1992-06-12 1995-05-30 Lewis; Michael E. Prevention and treatment of peripheral neuropathy

Also Published As

Publication number Publication date
AU683215B2 (en) 1997-11-06
GR3032844T3 (en) 2000-07-31
HU9403544D0 (en) 1995-02-28
NO309705B1 (no) 2001-03-19
EP0659083A4 (de) 1996-03-20
FI945840A0 (fi) 1994-12-12
NZ253867A (en) 1996-08-27
AU4526293A (en) 1994-01-04
EP0659083A1 (de) 1995-06-28
WO1993025219A1 (en) 1993-12-23
HU217543B (hu) 2000-02-28
US5633228A (en) 1997-05-27
NO944780D0 (no) 1994-12-09
NO944780L (no) 1994-12-09
NZ280523A (en) 1997-07-27
ES2140463T3 (es) 2000-03-01
CA2136969C (en) 2009-03-24
JPH07507799A (ja) 1995-08-31
DE69327402T2 (de) 2000-05-04
DE69327402D1 (de) 2000-01-27
PT659083E (pt) 2000-05-31
EP0659083B1 (de) 1999-12-22
HUT70450A (en) 1995-10-30
US5648335A (en) 1997-07-15
DK0659083T3 (da) 2000-06-13
US5569648A (en) 1996-10-29
JP3623502B2 (ja) 2005-02-23
CA2136969A1 (en) 1993-12-23

Similar Documents

Publication Publication Date Title
DE69327402D1 (de) Vorbeugung und behandlung der peripheren neuropathie
UA26213C2 (uk) Засіб для профілактики та лікуваhhя остеопорозу та фармацевтичhа композиція hа їх осhові
DE69427869D1 (de) Botulinumtoxine zur behandlung von hyperhydrosis
DE122009000012I1 (de) Substituierte pyrazolyl-benzolsulfonamide zur behandlung von entzundungen.
DE69406898D1 (de) Vorrichtung zur behandlung von gehirnschädigungen durch gammastrahlung und behandlungsgerät
ATE118172T1 (de) Zusammensetzung und verfahren für die behandlung von osteoporose bei säugetieren.
DE69318902D1 (de) Rapamycin zur Behandlung von Morbus Crohn, ulcerativer Colitis und ulcerative Proctitis
RU94046291A (ru) Способ профилактики и лечения периферической невропатии, композиция, содержащая инсулин-подобный фактор роста i
DE69220051D1 (de) Vorrichtung zur Behandlung von Getreide
EP0675723A4 (de) Biphosphonat/östrogen-therapie zur behandlung und prävention von knochenverlust.
DE69304233D1 (de) Vorrichtung zur Behandlung von Wasser
DE69527140D1 (de) Wirkstoff zur prävention oder behandlung von osteoporose
DE69509843D1 (de) Apparat zur Behandlung z.B. von Poststücken
ATE190843T1 (de) Zubereitungen zur behandlung von impotenz, die ein alpha-1 inhibitor und ein alpha-2 inhibitor enthalten
SG48733A1 (en) Use of il-10 to prevent or treat insulin-dependent diabetes mellitus
DE59209268D1 (de) Verfahren zur thermochemisch-thermischen behandlung von einsatzstählen
DE69018799D1 (de) IGF-I zur Behandlung von Nebeneffekten der Steroidtherapie.
IL109419A0 (en) Enzyme compositions for the treatment of sticky cotton fiber and method for treating them with such enzyme compositions
ATE178206T1 (de) Verfahren zur vorbeugung und behandlung von durch chemotherapie ausgelöster alopezie
DE68907569D1 (de) Mittel zur behandlung oder vorbeugung von aids.
DE69403871D1 (de) Vorrichtung zur Behandlung von Oberflächen
DE59100861D1 (de) Kontinue-verfahren zur behandlung von textilen warenbahnen und entsprechende anlage.
DE69412178D1 (de) Apparat zur Behandlung von Lagen
DE69023006D1 (de) Verfahren zur behandlung von thrombocytopenie und dafür geeignete pharmazeutische zusammensetzungen.
DE69906701D1 (de) Topische verwendung von loperamid zur behandlung mikrobieller infektionen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification